title: [Indirubin inhibits the proliferation of prostate cancer PC-3 cells].
abstract: OBJECTIVE
  To explore the antitumoral effect of indirubin on androgen-independent prostate cancer PC-3 cells and its possible mechanisms.
  
  
  METHODS
  We measured the inhibitory effect of indirubin on the proliferation of prostate cancer PC-3 cells using MTT assay, detected their cell cycles by flow cytometry, and determined the expressions of the cell cycle regulatory protein cyclin D1 and its related downstream gene c-myc by Western blot.
  
  
  RESULTS
  The viability of the PC-3 cells was significantly decreased by indirubin in a concentration-dependent manner, reduced to 52. 2% and 13. 6% at 5 and 10 µmol/L, respectively. The cell cycle of the PC-3 cells was markedly inhibited by indirubin at 5 µmol/L, with the cells remarkably increased in the G0 and G1 phases and decreased in the S and G2/M phases. Meanwhile, indirubin also inhibited the expressions of cyclin D1 and c-myc in the Wnt signaling pathway.
  
  
  CONCLUSIONS
  Indirubin can suppress the proliferation of androgen-independent prostate cancer PC-3 cells, which may be associated with its inhibitory effect on the cell cycle and Wnt signaling pathway.
authors.forename: Yun-fei
authors.initials: YF
authors.lastname: Wei
authors.forename: Jian
authors.initials: J
authors.lastname: Su
authors.forename: Zhong-lei
authors.initials: ZL
authors.lastname: Deng
authors.forename: Chen
authors.initials: C
authors.lastname: Zhu
authors.forename: Lin
authors.initials: L
authors.lastname: Yuan
authors.forename: Zi-jie
authors.initials: ZJ
authors.lastname: Lu
authors.forename: Qing-yi
authors.initials: QY
authors.lastname: Zhu
mesh_terms: D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000494:pharmacology*; D002453:Cell Cycle / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects*; D002470:Cell Survival / Q000187:drug effects; D004396:Coloring Agents; D019938:Cyclin D1 / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D016259:Genes, myc; D006801:Humans; D007211:Indoles / Q000008:administration & dosage / Q000494:pharmacology; D008297:Male; D064129:Prostatic Neoplasms, Castration-Resistant / Q000188:drug therapy* / Q000473:pathology; D016271:Proto-Oncogene Proteins c-myc / Q000378:metabolism; D013778:Tetrazolium Salts; D013844:Thiazoles
chemical_list: D000903:Antibiotics, Antineoplastic; C530104:CCND1 protein, human; D004396:Coloring Agents; D007211:Indoles; C489427:MYC protein, human; D016271:Proto-Oncogene Proteins c-myc; D013778:Tetrazolium Salts; D013844:Thiazoles; D019938:Cyclin D1; C022616:thiazolyl blue; C027185:indirubin